Transdermal delivery of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): a mini review
DOI:
https://doi.org/10.22219/farmasains.v4i2.11369Keywords:
Transdermal, NSAIDs, Nanoparticle, Iontophoresis.Abstract
The transdermal route has several advantages over the oral route, especially for the drugs which significantly experience the first-pass effect in the liver. Another advantage of drug administration via the transdermal route is its non-invasive way and can be used by patients themselves. Also, it allows long-term use, thereby increasing patient compliance and is generally inexpensive. The development of transdermal preparation itself is not easy because of the permeability factor of drug ingredients through the skin is relatively low compared to the gastrointestinal route or mucous membrane because the skin is part of the body's defense system and prevents foreign materials to entering the body. The biggest challenge for drug administration via the transdermal route is that the limitations of drugs can be administrated through this route. NSAIDs are drugs that are widely used in chronic conditions and can cause serious gastrointestinal side effects. Therefore the transdermal route is expected to be a promising alternative in the future. The drug-loaded nanoparticle delivered using the iontophoresis method can improve the bioavailability of NSAIDs via the transdermal route.
Downloads
References
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011). BDDCS Applied to Over 900 Drugs. The AAPS Journal, 13(4), 519–547. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
Desai, P., Patlolla, R. P., & Singh, M., (2010). Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Molecular Membrane Biology, 27(7), 247–259.
Dhote, V., Bhatnagar, P., Mishra, P. K., Mahajan, S. C., & Mishra, D. K. (2012). Iontophoresis: A potential emergence of a transdermal drug delivery system. Scientia Pharmaceutica, 80(1), 1–28.
El-Leithy, E. S., Ibrahim, H. K., & Sorour, R. M. (2015). In vitro and in vivo evaluation of indomethacin nanoemulsion as a transdermal delivery system. Drug Delivery, 22(8), 1010–1017.
Fini, A., Fazio, G., & Feroci, G. (1995). Solubility and solubilization properties of non-steroidal anti-inflammatory drugs. International Journal of Pharmaceutics, 126(1–2), 95–102.
Florence, A. T., & Attwood, D. (2015). Physicochemical Principles of Pharmacy: In Manufacture, Formulation and Clinical Use. London, UK: Pharmaceutical Press.
Mudshinge, S. R., Deore, A. B., Patil, S., & Bhalgat, C. M. (2011). Nanoparticles: Emerging carriers for drug delivery. Saudi Pharmaceutical Journal, 19(3), 129–141.
Prausnitz, M. R., & Robert, L. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
Prausnitz, M. R., Elias, P. M., Franz, T. J., Schmutz, M., Tsai, J., Menon, G. K., Holleran, W. M., & Feingold, K. R. (2012). Skin Barrier and Transdermal Drug Delivery. In J. P. Callen., L. Cerroni., W. R. Heymann., G. J. Hruza., A. J. Mancini., J. W. Patterson., ... T. Schwarz (Eds.), Dermatology (3rd Ed., pp. 2065-2073). Philadelphia, PA: Elsevier Saunders.
Prow, T. W., Grice, J. E., Lin, L. L., Faye, R., Butler, M., Becker, W., Wurm, E. M., Yoong, C., Robertson, T. A., & Soyer, H. P. (2011). Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery Reviews, 63(6), 470–491.
Tomoda, K., Terashima, H., Suzuki, K., Inagi, T., Terada, H., & Makino, K. (2011). Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids and Surfaces B: Biointerfaces, 88(2), 706–710.
Tomoda, K., Terashima, H., Suzuki, K., Inagi, T., Terada, H., & Makino, K. (2012). Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids and Surfaces B: Biointerfaces, 92, 50–54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Raditya Weka Nugraheni
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
